This is the authors' abstract. We don't add key points for this paper.
Cancer development involves complex interactions between tumors and the host microenvironment. Throughout this process, dynamic regulation of the actin cytoskeleton is crucial for tumor invasion, metastasis, and immune evasion. Transgelin 2 (TAGLN2), a key regulator of the cytoskeleton, significantly influences tumor progression by integrating actin dynamics, signaling pathways, and epigenetic modifications. Despite its promising role as a biomarker and therapeutic target in pan-cancer contexts, further analysis is required to clarify its tissue-specific expression patterns and resolve inconsistencies in its reported molecular mechanisms. This paper aims to elucidate the unique molecular and biochemical characteristics of TAGLN2, systematically summarize its expression profiles across diverse clinical tumors, and evaluate associated signaling pathways. Additionally, it examines the mechanisms underlying TAGLN2's contribution to tumorigenesis and tumor progression. Furthermore, current therapeutic strategies targeting TAGLN2 are discussed, highlighting future research directions and the potential for clinical translation, especially in tumor immunotherapy. Future studies should emphasize understanding the dynamic interactions mediated by TAGLN2 within the tumor microenvironment (TME). The development of precision therapies targeting cytoskeletal remodeling and immune metabolic regulation holds great promise for overcoming tumor heterogeneity and therapeutic resistance.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: